PainChek's Annual Recurring Revenue Grows to AU$4 Million as of January-End

MT Newswires Live
01/30

PainChek (ASX:PCK) said its annual recurring revenue grew to AU$4 million at the end of January with the implementation of licenses, and it anticipates an annual recurring revenue of AU$5.6 million after all licenses have been implemented, according to a Friday Australian bourse filing.

The company also has a pipeline for about AU$1.9 million in annual recurring revenue under negotiation across US, Canada, UK, and Australia-New Zealand, the filing said.

The company plans to continue negotiating with the Centers for Medicare & Medicaid Services in the US for an additional specific PainChek Current Procedural Terminology reimbursement code by April, per the filing.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10